Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics

Journal of Infectious Diseases

Volumn 182, Issue 5, 2000, Pages 1425-1436

  Hoe, Nancy P ^a   Kordari, Parichher ^b   Cole, Robert ^a   Liu, Mengyao ^a   Palzkill, Timothy ^b   Huang, Wanzhi ^b   McLellan, Duncan ^c   Adams, Gerald J ^b   Hu, Mary ^e   Vuopio Varkila, Jaana ^g   Cate, Thomas R ^b   Pichichero, Michael E ^f   Edwards, Kathryn M ^d   Eskola, Juhani ^g   Low, Donald E ^h   Musser, James M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ID Vaccine   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL PROTEIN; COMPLEMENT INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CHILD; EPIDEMIC; HUMAN; MAJOR CLINICAL STUDY; PHAGE DISPLAY; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS GROUP A;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; COMPLEMENT INACTIVATORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGE; MOLECULAR SEQUENCE DATA; SEROTYPING; STREPTOCOCCUS PYOGENES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033791050     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315882     Document Type: Article

References (42)

1. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function
2. The revival of group A streptococcal diseases, with a commentary on staphylococcal toxic shock syndrome
3. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: Clonal diversity and pyrogenic exotoxin expression
4. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: Recent intercontinental spread of a subclone causing episodes of invasive disease
5. Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland
6. Genetic diversity in T1M1 group A streptococci in relation to clinical outcome of infection
7. A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints
8. Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves
9. Characterization of group A Streptococcus strains recovered from Mexican children with pharyngitis by automated DNA sequencing of virulence-related genes: Unexpectedly large variation in the gene (sic) encoding a complement-inhibiting protein
10. Hypervariability generated by natural selection in an extracellular complement-inhibiting protein of serotype M1 strains of group A Streptococcus
11. Rapid molecular genetic subtyping of serotype M1 group A Streptococcus strains
12. Variation in sic gene encoding complement-inhibiting protein of Streptococcus pyogenes serotype M1 isolates in Japan
13. Nucleotide substitutions and small-scale insertion produce size and antigenic variation in group A streptococcal M1 protein
14. Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization
15. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments
16. Evaluation of the latency-associated nuclear antigen (ORF73) of Kaposi's sarcoma-associated herpesvirus by peptide mapping and bacterially expressed recombinant Western blot assay
17. Use of the arabinose p(bad) promoter for tightly regulated display of proteins on bacteriophage
18. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter
19. Immunoglobulin A: Strategic defense initiative at the mucosal surface
20. Role of mga in growth phase regulation of virulence genes of the group A Streptococcus
21. Biological properties of a Streptococcus pyogenes mutant generated by Tn916 insertion in mga
22. Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor
23. Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: Cleavage by streptococcal cysteine protease
24. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins
25. A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties
26. Persistence of type-specific antibodies in man following infection with group A streptococci
27. Acquisition of group A streptococcal M protein antibodies
28. Factors influencing antibody responses to streptococcal M proteins in humans
29. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989
30. Correlation between serum TNFα and IL6 levels and severity of group A streptococcal infections
31. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease
32. Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity
33. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome
34. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome
35. Vaccination with streptococcal extracellular cysteine protease (interleukin-1β convertase) protects mice against challenge with heterologous group A streptococci
36. Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera
37. Invasive group A streptococcal disease in the Netherlands: Evidence for a protective role of anti-exotoxin A antibodies
38. Protective immunity to the group A Streptococcus may be only strain specific
39. New protective antigen of group A streptococci
40. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus
41. A natural variant of the cysteine protease virulence factor of group A streptococcus with an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins αvβ3 and αIIbβ3